[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"female-fertility-decline\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:female-fertility-decline":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100638840",false,"NCT07581444","Early Prevention and Precision Management of Female Fertility Decline","Development and Evaluation of a Precision Prevention Strategy for Early Female Fertility Decline Based on OvaRePred-Plus: A Multicenter Cluster Randomized Controlled Trial","OvaRePred-Plus","Inclusion Criteria:\n\n* Women aged 20-40 years\n* Diagnosed with infertility or planning assisted reproductive treatment\n* Regular menstrual cycles (21-35 days)\n* Willing to participate in a 12-week lifestyle intervention program\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Known chromosomal abnormalities or genetic disorders affecting fertility\n* History of ovarian surgery or severe ovarian damage\n* Diagnosed endocrine disorders affecting reproduction (e.g., uncontrolled thyroid disease, hyperprolactinemia)\n* Severe systemic diseases (e.g., cardiovascular, hepatic, renal diseases)\n* Current pregnancy or breastfeeding\n* Use of hormonal medications or supplements affecting ovarian function within the past 3 months\n* Participation in another clinical trial within the past 3 months","FEMALE","20 Years","40 Years",{"count":20,"type":21},384,"ESTIMATED","INTERVENTIONAL",[24],"NA","Female fertility decline has become an important public health issue in China, with a substantial proportion of women of reproductive age experiencing reduced ovarian reserve. However, effective tools for early identification and large-scale prevention of fertility impairment in the general population are still lacking.\n\nThis study aims to develop and evaluate a precision prevention strategy for early female fertility decline based on the OvaRePred-Plus model, which integrates ovarian reserve markers, lifestyle factors, and reproductive health indicators. A multicenter, cluster randomized controlled trial will be conducted across six medical centers in China, enrolling women aged 20-40 years identified as having early signs of fertility decline.\n\nParticipants will be allocated to either an intervention group receiving a comprehensive health management program (including dietary optimization, nutritional supplementation, physical activity, and sleep improvement) or a control group receiving routine clinical care. The intervention will last for 12 weeks.\n\nThe primary outcome is the change in fertility score assessed by the OvaRePred-Plus model. Secondary outcomes include changes in ovarian reserve markers (e.g., AMH), menstrual status, ultrasound parameters, and reproductive outcomes.\n\nThis study is expected to provide evidence for a scalable and cost-effective strategy for early prevention and management of female fertility decline.",[27,28,29,30],"Female Fertility Decline","Diminished Ovarian Reserve","Reproductive Health","Infertility Prevention","NOT_YET_RECRUITING","2026-05-06",{"date":34,"type":35},"2026-05-12","ACTUAL",{"date":37,"type":21},"2026-06",{"date":39,"type":21},"2026-12",{"name":41,"class":42},"Peking University Third Hospital","OTHER",""]